Hutchison China MediTech presented the results of the Phase III study of surufatinib in advanced neuroendocrine tumours – extra-pancreatic – at the 2019 European Society for Medical Oncology Congress (ESMO). The study met the predefined primary endpoint of progression-free survival (PFS) early. Patients treated with surufatinib were 67% less expected to see their disease progress or die compared with patients on placebo control, assessed by local investigators.
In the SANET-ep – Phase III study in patients with extra-pancreatic (non-pancreatic) NET in China, the efficacy of surufatinib was seen across all subgroups and supported by statistically significant improvement.
The safety and tolerability data of surufatinib in western patients were presented at ESMO 2019, including data on 15 patients with heavily treated pancreatic NET. The study confirmed 300mg as the recommended Phase 2 dose (RP2D). Preliminary data demonstrates promising anti-tumour activity in pancreatic NET patients, with objective response rate (ORR) of 13.3% and disease control rate (DCR) of 73.3%.